Samsung Biologics Co.,Ltd. provided dividend guidance for the year 2021. The company expected to remain steady at the mid-20% range amid full operations at Plants 1 and 2, and near-full operations at Plant 3. The high utilization rate is also expected to drive an increase in the annual operating profit.